Clinical trial NCT00721162: Study of Ramucirumab in Ovarian Cancer
Official title: A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Carcinoma
Keywords: Ovarian Cancer,
Fallopian Tube Cancer
Primary Peritoneal Carcinoma
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2008-07-23
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if ramucirumab given as monotherapy is effective in the treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.

Detailed description: Current chemotherapies used to treat ovarian cancer participants include doxorubicin, topotecan, and paclitaxel, to mention a few. Doxorubicin was studied in ovarian cancer participants that were refractory to paclitaxel and platinum-based chemotherapy agents. Inhibition of angiogenesis is considered a promising approach to the treatment of cancer. Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis and is likely an important therapeutic target in persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. VEGF is overexpressed in ovarian tissue and may be the most important single tumor angiogenic factor. Phase 1 studies currently nearing completion with ramucirumab have demonstrated safety and tolerability at clinically relevant doses, with preliminary evidence of clinical efficacy in ovarian cancer participants. Therefore, ImClone Systems plans to conduct a Phase 2 trial to assess the safety and efficacy of ramucirumab in participants with platinum-refractory persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Eligibility criteria: Inclusion Criteria:

Each participant must meet the following criteria to be enrolled in this study:

1. The participant has recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Histologic documentation of the original primary tumor is required via a pathology report
2. The participant has at least one unidimensional-measurable target lesion \[≥ 2 centimeter (cm) with conventional techniques, or ≥ 1 cm by spiral computed tomography (CT) or magnetic resonance imaging (MRI)\], as defined by Response Evaluation Criteria in Solid Tumors (RECIST). Tumors within a previously irradiated field will be designated as "nontarget" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
3. The participant has recovered to Grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v3.0) from the effects of recent surgery, radiotherapy, chemotherapy, hormonal therapy, or other targeted therapies for ovarian cancer, with the exception of alopecia or peripheral neuropathy (which must have resolved to Grade ≤ 2). Any other prior therapy directed at the malignant tumor must be discontinued at least three weeks prior to the first dose of study medication, or hormonal therapy discontinued at least one week prior to the first dose of study medication. Continuation of hormone replacement therapy is permitted
4. The participant has completed at least one platinum-based chemotherapeutic regimen for management of primary disease, and must have at least one of the following: a platinum-free interval of \< 12 months after the final dose of primary platinum-based therapy, progression during platinum-based therapy, or persistent disease after platinum-based therapy
5. The participant has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1 at study entry
6. The participant has adequate hematological functions \[absolute neutrophil count (ANC) ≥ 1200 cells/microliter (uL), hemoglobin ≥ 9 grams/deciliter (g/dL), and platelets ≥ 100,000 cells/uL\]
7. The participant has adequate hepatic function \[bilirubin ≤ 1.5 times the upper limit of normal (ULN); aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤ 3.0 times ULN, or ≤ 5.0 times ULN if the transaminase elevation is due to liver metastases\]
8. The participant has adequate renal function \[serum creatinine ≤ 1.5 x ULN or creatinine clearance (measured or calculated) ≥ 60 milliliters/minute (mL/min)\]
9. The participant's urinary protein is ≤ 1+ on dipstick or routine urinalysis (UA). If urine dipstick or routine analysis indicated ≥ 2+ proteinuria, then a 24-hour urine must be collected and must demonstrate \< 1000 milligrams (mg) of protein in 24 hours to allow participation in the study
10. The participant has adequate coagulation function, as defined by international normalized ratio (INR) ≤ 1.5 and a partial thromboplastin time (PTT) ≤ 1.5 X ULN if not receiving anticoagulation therapy. Participants on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin, and if on warfarin must have therapeutic INR and have no active bleeding (defined as within 14 days of first dose of study medication) or pathological condition that carries a high risk of bleeding (example, tumor involving major vessels or known varices)
11. For participants who have received anthracycline therapy, the left ventricular ejection fraction (LVEF) must be within normal institutional range by a pretreatment echocardiogram or multigated acquisition (MUGA) scan
12. If sexually active, the participant is post-menopausal, surgically sterile, or using effective contraception in the opinion of the investigator
13. The participant is ≥ 18 years of age
14. The participant has a life expectancy of ≥ 3 months
15. The participant is able to provide informed written consent and is amenable to compliance with protocol schedules and testing

Exclusion Criteria:

1. The participant has a concurrent active malignancy, other than adequately treated nonmelanomatous skin cancer or other noninvasive carcinoma or in situ neoplasm. A participant with previous history of malignancy is eligible provided that she has been disease-free for \> 3 years
2. The participant has received a noncytotoxic regimen (usually called targeted therapy such as bevacizumab) for recurrent or persistent disease. (Participants may have received a noncytotoxic regimen as primary treatment.)
3. The participant has received radiotherapy for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within 3 weeks (21 days) prior to the first dose of study medication
4. The participant has received prior radiotherapy to any portion of the abdominal cavity or pelvis other than for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last 3 years. \[Prior radiation for localized cancer (for example, of the breast, head and neck, or skin) is permitted, provided that it was completed \> 3 years prior to the first dose of study medication, and the participant remains free of recurrent or metastatic disease.\]
5. The participant has received prior chemotherapy for any abdominal or pelvic tumor, other than for the treatment of ovarian, fallopian tube, or primary peritoneal cancer \< 3 years prior to the first dose of study medication. Prior adjuvant chemotherapy for localized breast cancer is permitted, provided that it was completed \>3 years prior to the first dose of study medication, and that the participant remains free of recurrent or metastatic disease
6. The participant has undergone major abdominal surgery within 4 weeks (28 days) prior to first dose of study medication
7. The participant has a suspected impending bowel obstruction, based on clinical or radiographic criteria
8. The participant has received any hormonal therapy directed at the malignant tumor discontinued therapy within 1 week (7 days) prior to first dose of study medication
9. The participant has received any other prior therapy directed at the malignant tumor, including immunologic agents, within 3 weeks (21 days) prior to first dose of study medication
10. The participant has received previous treatment with ramucirumab
11. The participant has participated in clinical trials of experimental agents within 4 weeks (28 days) prior to first dose of study medication
12. The participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders
13. The participant has an ongoing or active infection requiring systemic antibiotics, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, myocardial infarction \< 6 months, Grade ≥ 2 peripheral vascular disease, poorly controlled hypertension despite standard medical management poorly controlled thrombotic or hemorrhagic disorder, psychiatric illness or social situations that would limit compliance with study requirements, or any other serious uncontrolled medical disorders in the opinion of the investigator
14. The participant has any history of brain metastases or leptomeningeal disease. Screening for central nervous system (CNS) involvement for testing asymptomatic participants is not required
15. The participant has known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness
16. The participant is pregnant \[confirmed by serum beta human chorionic gonadotropin (β-HCG) test\] or lactating

Primary outcomes:
measure: Percentage of Participants With Progression-Free Survival at 6 Months (PFS-6)
timeFrame: First Dose to 6 Months
measure: Objective Response Rate (ORR): Percentage of Participants With Complete Response (CR) and Partial Response (PR)
timeFrame: First dose to date of objective progressive disease /death or new anti-cancer therapy up to 34.6 months
Secondary outcomes:
measure: Progression-Free Survival (PFS)
timeFrame: First dose to measured progressive disease or death due to any cause up to 34.6 months
measure: Overall Survival at 1 Year (OS-1)
timeFrame: First dose to 12 months
measure: Overall Survival (OS)
timeFrame: First dose to death due to any cause up to 43.9 months
measure: Summary Listing of Participants Reporting Drug-Related Treatment-Emergent Adverse Events
timeFrame: First dose to 30 months
Other outcomes:
Locations:
city: Hollywood
country: United States
facility: ImClone Investigational Site
state: Florida
city: Orlando
country: United States
facility: ImClone Investigational Site
state: Florida
city: Chicago
country: United States
facility: ImClone Investigational Site
state: Illinois
city: Marrero
country: United States
facility: ImClone Investigational Site
state: Louisiana
city: Metairie
country: United States
facility: ImClone Investigational Site
state: Louisiana
city: Baltimore
country: United States
facility: ImClone Investigational Site
state: Maryland
city: Boston
country: United States
facility: ImClone Investigational Site
state: Massachusetts
city: Rochester
country: United States
facility: ImClone Investigational Site
state: Minnesota
city: Oklahoma City
country: United States
facility: ImClone Investigational Site
state: Oklahoma
city: Houston
country: United States
facility: ImClone Investigational Site
state: Texas
city: Seattle
country: United States
facility: ImClone Investigational Site
state: Washington
city: London
country: United Kingdom
facility: ImClone Investigational Site
city: Sutton
country: United Kingdom
facility: ImClone Investigational Site
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
citation: Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, Banerjee S, Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol. 2014 Sep;134(3):478-85. doi: 10.1016/j.ygyno.2014.06.029. Epub 2014 Jul 10.